Information  X 
Enter a valid email address

Nuformix PLC (NFX)

  Print      Mail a friend

Tuesday 24 November, 2020

Nuformix PLC

Appointment of Non-Executive Director

RNS Number : 2470G
Nuformix PLC
24 November 2020

Nuformix plc


Appointment of Dr Julian Gilbert as Non-Executive Director


Cambridge, UK - 24 November 2020:  Nuformix plc (LSE:NFX; "Nuformix", the "Company" or the "Group"), a drug re-purposing specialist, is pleased to announce the appointment of Dr Julian Gilbert to the Board of Nuformix as a Non-Executive Director with immediate effect.


Julian has more than 30 years of commercial and technical experience in the pharmaceutical industry gained at a number of companies including Chiroscience Plc, Mundipharma International Limited, British Technology Group plc (BTG) and Smith Kline & French (now GlaxoSmithKline plc). Most recently, Julian was co-founder and CEO of Acacia Pharma Group plc (Acacia), raising c.£100m in private and public funding and leading its flotation on Euronext in 2018. Julian resigned from Acacia on 31 July 2019. Prior to Acacia, he was co-founder and Commercial Director of Arakis Limited which was sold to Sosei in 2005 for £107 million. Julian has worked in business development since 1992 and has led multiple business development projects.


Julian has a degree in pharmacy and a PhD in pharmaceutics, both from the University of Nottingham.


Julian will be appointed as a member of the Nomination & Audit Committees.


The Board is also undertaking a search for an additional independent Non-Executive Director with recent and relevant financial experience.



Dr Chris Blackwell, Executive Chairman, commented:

"It's a pleasure for us to welcome Julian to the Board. Julian's knowledge and experience will be extremely valuable as the Company moves forward with its near-term strategic priorities focussed on business development and licensing opportunities. "

Commenting on his appointment, Dr Julian Gilbert said:

"I am delighted to be joining the Board of Nuformix, and look forward to supporting the Company achieve key strategic objectives."


No further information is required to be disclosed pursuant to LR 9.6.13 R.

The person responsible for arranging the release of this announcement on behalf of the Company is Dr Chris Blackwell, Executive Chairman.



Nuformix plc

Dr Chris Blackwell, Executive Chairman

Fleur Wood, Investor Relations

Email: [email protected]



+44 (0)1223 627222


Novum Securities Limited

Jon Belliss / Colin Rowbury 


+44 (0)20 7399 9427



About Nuformix

Nuformix is a pharmaceutical development company focused on unlocking the therapeutic potential and value of known drugs to develop new novel medicines which provide therapeutic and commercial advantages to the currently available drug form. Nuformix's model of repurposing drugs utilises many technologies but is focussed on its acknowledged expertise in the use of cocrystal technology through which the Group has developed and patented novel forms of small molecules. Its platform is not therapy-specific but instead has broad application across a wide range of indications. Using its technology, the Group is developing proprietary medicines for its own development pipeline and in partnership with pharmaceutical and biotech companies.


Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX. For more information please visit .




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t